Bris­tol-My­ers opens up the Phase 0 path­way in test­ing its new can­cer ther­a­pies, fol­low­ing in Cel­gene’s foot­steps

Find­ing out as much as you can as fast as you can about your new can­cer drug has be­come a ma­jor theme in on­col­o­gy R&D, where bil­lions can lie on the line — de­pend­ing on the ul­ti­mate suc­cess of your rapid-fire de­vel­op­ment strat­e­gy. And few ma­jor league phar­ma out­fits un­der­stand that chal­lenge bet­ter than Bris­tol-My­ers Squibb, which has faced more than its share of mis­di­rec­tions on strat­e­gy.

So it’s par­tic­u­lar­ly in­ter­est­ing to see Bris­tol-My­ers tie-up with Seat­tle-based Presage Bio­sciences on Phase O test­ing, which will use mi­cro­dos­es of mul­ti­ple drugs and com­bos on pa­tients to gauge their phar­ma­co­dy­nam­ic ef­fects. That way re­searchers can help de­ter­mine if they’re on the right track as they lay out plans to de­vel­op drugs in much more ex­ten­sive stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA